$4.40
-0.07-1.57%
Last update: Oct 23, 4:05 AM
Abeona Therapeutics Inc (ABEO) Stock Price, Quote, News & History
ABEONASDAQ
FDA approves Zevaskyn as the first cell-based gene therapy for RDEB wounds after strong results in pivotal and long-term studies.
You can purchase shares of Abeona Therapeutics (NASDAQ:ABEO) through any online brokerage.
Other companies in Abeona Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Abeona Therapeutics has a consensus price target of $19.88.
The stock price for Abeona Therapeutics (NASDAQ: ABEO) is $4.41 last updated October 23, 2026 at 4:05 AM EDT.
There are no upcoming dividends for Abeona Therapeutics.
Abeona Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Abeona Therapeutics.
Abeona Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene...
